Cost-Effectiveness of CYP2C19 Genotype-Guided Antiplatelet Therapy for Acute Minor Ischemic Stroke and High-Risk TIA in China
A pharmacoeconomic study evaluated whether personalizing antiplatelet therapy based on CYP2C19 genetic testing (using cilostazol or ticagrelor) is cost-effective compared to standard clopidogrel plus aspirin treatment for minor stroke and high-risk transient ischemic attack in China. The analysis found genotype-guided strategies were cost-effective with incremental cost-effectiveness ratios below accepted thresholds, with robust results across sensitivity analyses.